Codexis, Inc. (CDXS): Price and Financial Metrics
CDXS Price/Volume Stats
| Current price | $2.90 | 52-week high | $4.91 |
| Prev. close | $2.86 | 52-week low | $1.45 |
| Day low | $2.88 | Volume | 192,442 |
| Day high | $3.03 | Avg. volume | 562,552 |
| 50-day MA | $3.31 | Dividend yield | N/A |
| 200-day MA | $2.58 | Market Cap | 203.88M |
CDXS Stock Price Chart Interactive Chart >
Codexis, Inc. (CDXS) Company Bio
Codexis, Inc. develops biocatalysts for the pharmaceutical and fine chemicals markets in the United States and internationally. The company offers Codex biocatalyst panels and kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. The company was founded in 2002 and is based in Redwood City, California.
Latest CDXS News From Around the Web
Below are the latest news stories about CODEXIS INC that investors may wish to consider to help them evaluate CDXS as an investment opportunity.
Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108Company to retain economic interest in biotherapeutic asset while removing cash burn from development and commercialization costsREDWOOD CITY, Calif., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into a purchase agreement with Nestlé Health Science, a globally recognized leader in the field of nutritional science, for CDX-7108, an investigational therapy for the potential treatment of exocrine pancreatic insu |
Codexis, Inc. (NASDAQ:CDXS) Stock Rockets 41% But Many Are Still Ignoring The CompanyCodexis, Inc. ( NASDAQ:CDXS ) shares have continued their recent momentum with a 41% gain in the last month alone... |
Is It Time To Consider Buying Codexis, Inc. (NASDAQ:CDXS)?Codexis, Inc. ( NASDAQ:CDXS ), might not be a large cap stock, but it received a lot of attention from a substantial... |
Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA PolymeraseDeal creates strategic collaboration to enable more efficient RNA therapeutic development, providing a path to GMP-grade Codexis enzymesREDWOOD CITY, Calif. and FARGO, N.D., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Aldevron, a global leader in the custom development and manufacture of plasmid DNA, RNA and proteins for the biotech industry, whereby Aldevron will acquire a global excl |
Codexis Announces Achievement of Gram-scale Synthesis with its ECO Synthesis™ PlatformMilestone enables Codexis engineers to model the manufacturing process for RNAi therapeutics Company remains on track to initiate pre-commercial customer testing in 2024 REDWOOD CITY, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has achieved gram-scale synthesis with its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology. This critical technical milestone demonstrates the preparative-scale manufacture o |
CDXS Price Returns
| 1-mo | -15.94% |
| 3-mo | 7.61% |
| 6-mo | 76.83% |
| 1-year | -30.46% |
| 3-year | -87.95% |
| 5-year | -84.90% |
| YTD | -4.92% |
| 2023 | -34.55% |
| 2022 | -85.10% |
| 2021 | 43.24% |
| 2020 | 36.52% |
| 2019 | -4.25% |
Continue Researching CDXS
Here are a few links from around the web to help you further your research on Codexis Inc's stock as an investment opportunity:Codexis Inc (CDXS) Stock Price | Nasdaq
Codexis Inc (CDXS) Stock Quote, History and News - Yahoo Finance
Codexis Inc (CDXS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...